The most common reason physicians hesitate before introducing stem cell banking to patients is not skepticism about the science. It is uncertainty about what they are allowed to say. The distinction between permissible and impermissible language in this space is precise, and getting it wrong carries real professional and regulatory risk. This guide provides a clear compliance framework: what physicians can say, what they cannot say, why the distinction matters, and a model patient conversation that demonstrates how to introduce banking accurately and professionally.
TLDR: Physicians introducing stem cell banking to patients can accurately describe what banking is (preservation of autologous tissue for potential future use in FDA-regulated pathways), discuss the clinical trial pipeline in factual terms, and explain the regulatory framework. They cannot make disease treatment claims, promise specific outcomes, or imply FDA approval of banking as a therapy. This post provides the exact language framework and a model patient conversation.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. The language framework in this post is provided for educational purposes only and does not constitute legal, regulatory, or compliance advice. Physicians should consult their own legal and compliance counsel before implementing any patient communication protocols in their practice.
A physician who has worked through the banking model, the market context, and the regulatory framework still tends to hit the same last obstacle before acting: “If I bring this up with a patient and they ask me whether it will help their arthritis, or their multiple sclerosis, or their back pain, what do I say?” The fear of saying the wrong thing, of inadvertently making a claim that triggers a complaint or a regulatory inquiry, keeps more physicians on the sideline than any other concern.
The good news is that the compliance line in this space is not vague. It is specific, documented, and navigable. The FDA’s framework for what constitutes a prohibited disease claim versus a permissible educational statement is clearly defined. The distinction is not between enthusiasm and caution. It is between describing what banking is and claiming what banking does. A physician who understands that distinction can have this conversation with every qualifying patient in their practice.
This post provides three things: the compliance framework in plain language, a structured list of permissible and impermissible statements with the reasoning behind each, and a model patient conversation that demonstrates how the framework works in a real clinical exchange.
The Regulatory Foundation for This Framework
Section 361 HCT/P and What It Permits
Adipose tissue banking is regulated under FDA Section 361 HCT/P guidelines at 21 CFR Part 1271. Under this framework, banking is compliant when it involves minimal manipulation of autologous tissue preserved for potential future use in homologous applications. The framework does not authorize disease treatment claims, and the Section 361 pathway is explicitly separate from the Section 351 biologics pathway that governs products marketed as treatments for specific indications. Save My Fat’s overviews of FDA regulations for adipose tissue and 21 CFR Part 1271 walk through the framework in physician-appropriate depth. The FDA’s own tissue products page is the primary source.
What the FDA Has Warned Against
The FDA has taken enforcement action against providers and clinics that market cellular products with disease treatment claims, including claims that stem cell therapies treat arthritis, multiple sclerosis, autism, COPD, Parkinson’s disease, and other specific conditions. The agency’s consumer alert documents the enforcement rationale in consumer-facing terms. These enforcement actions apply to clinics making unapproved treatment claims. They do not apply to physicians accurately describing a compliant banking service.
The Line Is Between Description and Claim
A physician who accurately describes what banking is, a preservation service for autologous tissue for potential future use in FDA-regulated pathways, is making a permissible educational statement. A physician who tells a patient that banking will treat their osteoarthritis, improve their skin, or address their autoimmune condition is making an unapproved disease treatment claim. That line is the compliance framework in a single sentence. Save My Fat’s comparison of banking vs. stem cell treatment clinics illustrates the practical distinction with patient-facing language.
The Permissible Language Framework
The table below gives a side-by-side comparison of what physicians can and cannot say across the most common categories of patient questions. This is the core deliverable of the post. Every permissible statement describes what banking is. Every impermissible statement claims what banking does.
| Category | Permissible | Impermissible |
|---|---|---|
| What banking is | “Banking preserves your own stem cells for potential future use in FDA-regulated pathways.” | “Banking will give you stem cells to treat your condition.” |
| The science | “Adipose tissue is one of the richest accessible sources of adult mesenchymal stem cells.” | “Your banked cells will regenerate your joints, skin, or nerves.” |
| Clinical trials | “There are more than 400 active clinical trials involving adipose-derived stem cells across multiple conditions.” | “Banking will make you eligible for stem cell treatment of your condition.” |
| Future access | “If relevant clinical trials or approved therapies become available, having banked cells positions you to access autologous options.” | “Once you bank, you can use your cells whenever you want for whatever you need.” |
| Timing | “Cells banked earlier in life are preserved at higher biological quality than cells banked later.” | “You need to bank now before you get too old for the cells to work.” |
| Family eligibility | “Under FDA Section 361 HCT/P criteria, first-degree and second-degree blood relatives may be eligible to use your banked cells in certain clinical contexts.” | “Your whole family can use your cells for any treatment they need.” |
| The FDA milestone | “The FDA approved the first mesenchymal stem cell product in December 2024 for a specific pediatric immune condition after a completed Phase 3 trial.” | “The FDA has approved stem cell therapy, so your treatment is coming soon.” |
The pattern across every row is the same. Permissible statements describe regulatory facts, scientific facts, or structural features of the banking service. Impermissible statements bridge those facts to claimed patient outcomes, which is the move the FDA’s enforcement framework treats as an unapproved therapeutic claim regardless of whether a product is being sold or merely discussed. The FDA physician guidance on expanded access is the reference text for how the agency distinguishes factual communication from promotional claims.
The Model Patient Conversation
The dialogue below is a model, not a script. It demonstrates how the permissible framework works in a real exam-room exchange. The patient is forty-seven, presenting for an annual wellness visit, with early-stage osteoarthritis in one knee, and has read about banking online before bringing it up at the end of the appointment.
Patient: I’ve been reading about stem cell banking, specifically banking fat stem cells. Is that something you think is worth doing?
Physician: It’s a real question and worth a real answer. Adipose tissue, fat, is one of the richest accessible sources of adult mesenchymal stem cells in the body. Banking is the process of collecting a small amount of fat, having a lab process and freeze those cells, and storing them for potential future use. The collection is a thirty-minute outpatient procedure under local anesthesia.
Patient: Would it help my knee?
Physician: That’s the specific question I want to be precise about. Banking is not a treatment. It doesn’t treat your knee or any other condition. What it does is preserve your cells at their current biological quality. There are more than four hundred active clinical trials involving adipose-derived stem cells right now, including trials in joint disease. As those trials produce results and therapies move toward approval, a patient who has banked their own cells has autologous options available. A patient who hasn’t banked doesn’t.
Patient: So it’s like insurance for future treatments?
Physician: That’s a reasonable way to think about it, with one important clarification. Banking doesn’t guarantee you’ll be eligible for any specific trial or therapy, and it doesn’t create access that doesn’t exist yet. What it does is preserve the option. The FDA approved the first mesenchymal stem cell product in December 2024, the first time the full approval pathway produced an MSC therapy. The pipeline behind that approval is large and active.
Patient: What does the banking actually involve for me?
Physician: A thirty-minute in-office procedure. Local anesthesia, a small amount of fat collected from your abdomen or flank, packaged and sent to a lab that processes and freezes the cells. You go home the same day. The cells are stored long-term. If and when you decide to access them, for a clinical trial, an expanded access program, or an approved therapy, they ship directly to your treating provider.
Patient: What does it cost?
Physician: It’s a cash-pay service. The all-in cost depending on the banking package is typically in the eight-thousand-to-fifteen-thousand-dollar range. That covers the harvest, processing, and long-term storage.
Patient: Is that covered by insurance?
Physician: No, it’s not a covered service. It’s elective preservation, similar in structure to egg freezing or cord blood banking.
The dialogue above is the full conversation needed. Every physician statement is either a factual description of what banking is, a factual reference to the regulatory or scientific landscape, or a precise redirect away from an implied treatment claim. At no point does the physician tell the patient that banking will treat their osteoarthritis, and at no point does the patient leave with a misunderstanding about what banking can do. That is the framework working as intended. Save My Fat’s overview of informed consent in regenerative medicine covers the consent architecture partner providers use, and the resource on finding legitimate clinical trials is a useful patient handoff for patients who want to continue researching on their own.
Handling the Harder Questions
Some patients press past the initial conversation. The three questions below are the ones most likely to surface, each with defensible suggested language.
“My neighbor went to a clinic and got stem cell injections for her hip. How is that different?”
Suggested response: There are clinics that offer stem cell injections as a treatment for specific conditions. Many of those clinics are operating in a regulatory gray zone. The FDA has issued warning letters to clinics making unapproved treatment claims with cellular products. Banking is different. Banking is preservation of your own tissue under FDA Section 361 guidelines. No treatment claims, no injections, compliant storage. The difference isn’t cosmetic. It’s the difference between a compliant preservation service and an unapproved therapy. Save My Fat’s overview of fake stem cell clinic red flags is a useful follow-up resource for patients who want specifics on how to recognize the enforcement-target pattern.
“Can my kids use my cells if they ever need them?”
Suggested response: Under FDA Section 361 HCT/P criteria, first-degree and second-degree blood relatives may be eligible to use your banked cells in certain clinical contexts. That is not a blanket guarantee. Eligibility depends on the specific pathway and the clinical situation at the time of use. But the framework does allow for relative use in applicable situations, and it is one of the structural features of Section 361 that differentiates autologous banking from allogeneic commercial products. Save My Fat’s overview of family eligibility walks through the regulatory basis.
“What if I want to use my cells for something that isn’t approved yet?”
Suggested response: There are legitimate pathways for accessing investigational therapies before approval. Clinical trial enrollment is one. Expanded access programs are another. If a condition you develop is being studied in an active trial that accepts autologous cells, having banked cells positions you for that option. Expanded access is a separate FDA pathway for patients with serious conditions and no other options. Neither pathway is guaranteed, but banking means the cells are there if either pathway opens. Save My Fat’s resources on expanded access programs and the Right to Try Act cover the specifics of both pathways, and the Reagan-Udall Foundation’s Expanded Access Navigator is the canonical public resource for patients evaluating the pathway.
What to Give Patients After the Conversation
The patient who leaves a good consultation with nothing to read loses context fast. Partner providers can equip every banking conversation with three reference handoffs: the Save My Fat patient education materials provided by Save My Fat on partnership, the savemyfat.com patient-facing pages as an independent reference library, and external resources for patients who want to verify claims on their own. Those external resources are the ClinicalTrials.gov search for active trials and the Reagan-Udall Navigator for expanded access. Save My Fat’s questions to ask before banking and the explainer on what ClinicalTrials.gov phases actually mean are the two most useful starting points for patients early in the research process.
Frequently Asked Questions
Do I need a specific disclaimer in my patient materials?
Save My Fat provides informed consent frameworks and patient education materials to all partner providers. These are built against the site’s compliance architecture. The Save My Fat overview of informed consent in regenerative medicine covers what those materials contain and how they are used. Physicians should also consult their own legal and compliance counsel for any practice-specific or state-specific requirements, particularly in Florida, Utah, and Nevada, where state statutes add specific informed-consent language to the federal framework.
Can I market banking on my practice website?
Yes, with precise language. Permissible marketing describes what banking is, a preservation service for autologous adipose-derived cells under FDA Section 361 HCT/P guidelines, and refers to the clinical trial pipeline in factual terms. Impermissible marketing makes disease treatment claims, implies FDA approval of banking as a therapy, or promises specific patient outcomes. The FDA guidance documents database is the primary reference for the agency’s position on promotional communications, and 21 CFR Part 1271 remains the operative rule for the service itself.
Can I tell patients that their condition is being studied in clinical trials?
Yes, as a factual statement with appropriate precision. “There are active clinical trials studying adipose-derived stem cells in osteoarthritis” is a permissible factual statement. “Banking will make you eligible for stem cell treatment of your osteoarthritis” is not. The distinction is that the first statement describes the state of the research; the second implies an outcome for a specific patient. Save My Fat’s guide on finding legitimate clinical trials in 2026 covers the resources patients can use to do the verification themselves.
What happens if a patient asks me directly whether banking will cure their disease?
Be direct and precise. “Banking is not a treatment and does not treat, cure, or prevent any disease. It is a preservation service for your own cells for potential future use in FDA-regulated pathways. I can’t tell you that it will cure anything, because that’s not what banking is.” The Save My Fat complete guide to banking is the patient-facing reference for any patient who needs the distinction in writing.
Key Takeaways
The compliance line is between description and claim. Describing what banking is, is permissible. Claiming that banking treats a specific disease is not. Every physician communication about banking, whether in a patient conversation, on a practice website, or in patient education materials, should be read against that single distinction before it is delivered.
Permissible language covers what banking is, the science of adipose-derived stem cells, the clinical trial pipeline in factual terms, the timing rationale based on cell biology, family eligibility in precise regulatory terms, and the Ryoncil approval as a documented regulatory milestone. Each of these descriptions is grounded in a factual reference that a physician can cite if challenged.
Impermissible language includes disease treatment claims, promises of specific patient outcomes, implications that the FDA has approved banking as a therapy, statements about open-ended future access, and any communication that bridges factual science to a claimed clinical benefit for a specific patient’s condition. The FDA’s enforcement record is consistent in treating those bridges as unapproved therapeutic claims.
The model patient conversation demonstrates how the permissible framework works in a real clinical exchange. Every physician statement in the dialogue is either a factual description, a regulatory reference, or a precise redirect away from an implied treatment claim. The patient leaves the conversation accurately informed and without any misunderstanding about what banking can do.
Three harder patient questions recur across every practice: the unregulated clinic comparison, family eligibility, and pre-approval access. Each has a precise, defensible answer built from the same permissible framework, with the appropriate Save My Fat resource available as a patient handoff after the conversation ends.
Save My Fat provides informed consent frameworks, patient education materials, and the compliance architecture that makes this conversation professionally defensible. Partner providers are not building this from scratch.
Ready to Have This Conversation With Confidence?
Before contacting Save My Fat: adipose tissue banking is a preservation service for potential future use in FDA-regulated pathways, not a treatment or a guarantee of access to any specific clinical trial, therapy, or product. No adipose-derived product is FDA-approved for general disease treatment, and banking cannot be represented to patients as one. The language framework in this post is educational and does not constitute legal or regulatory advice. Physicians considering partnership should independently verify applicable state licensing and informed-consent requirements, particularly in Florida, Utah, and Nevada, which have stem cell-specific statutes.
The framework is clear. The language is precise. The patient conversation is navigable. What remains is having it.
Save My Fat partner providers receive informed consent frameworks, patient education materials, and the compliance architecture that makes this conversation professionally defensible from day one. You are not building this from scratch.
To review the full program structure, visit the provider program overview. To begin onboarding as a partner, visit the partner sign-up page.
Save My Fat provides adipose tissue banking services in partnership with L2 Bio for laboratory operations. Save My Fat does not provide medical treatments, clinical trial enrollment, or Expanded Access services.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
